Systematic exploration of cancer-associated microRNA through functional screening assays

Cancer Science

Volumn 102, Issue 9, 2011, Pages 1615-1621

  Izumiya, Masashi ^a,c   Tsuchiya, Naoto ^a   Okamoto, Koji ^b   Nakagama, Hitoshi ^a  

^a Division of Cancer Development System   (Japan)

^b NATIONAL CANCER CENTER RESEARCH INSTITUTE   (Japan)

^c UNIVERSITY OF TOKYO HOSPITAL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; MICRORNA; MICRORNA 10B; MICRORNA 122A; MICRORNA 124A; MICRORNA 125A; MICRORNA 125B; MICRORNA 15A; MICRORNA 16; MICRORNA 16 1; MICRORNA 17 92; MICRORNA 21; MICRORNA 22; MICRORNA 221; MICRORNA 222; MICRORNA 27A; MICRORNA 296; MICRORNA 29B; MICRORNA 34A; MICRORNA 34B; MICRORNA 34C; MICRORNA 378; MYC PROTEIN; PROTEIN P53; STAT3 PROTEIN; TRANSCRIPTION FACTOR E2F; TRANSCRIPTION FACTOR TWIST; UNCLASSIFIED DRUG; VIRUS VECTOR;

ANGIOGENESIS; APOPTOSIS; CANCER INHIBITION; CANCER THERAPY; CANCER TISSUE; CARCINOGENESIS; CELL CYCLE; CELL DEATH; CELL INVASION; CELL MATURATION; CELL PROLIFERATION; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENETIC ANALYSIS; GENOMIC INSTABILITY; HUMAN; METASTASIS; MICROARRAY ANALYSIS; MULTIPLEX ASSAY; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; REVIEW; RNA INTERFERENCE; SCREENING TEST; SINGLE PLEX ASSAY;

ANIMALS; CELL MOVEMENT; CELL PROLIFERATION; GENE EXPRESSION PROFILING; HUMANS; MICE; MICRORNAS; NEOPLASMS;

EID: 80051816992     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2011.02007.x     Document Type: Review

References (65)

1. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004; 116: 281-97.
2. Filipowicz W, Bhattacharyya SN, Sonenberg N. Mechanisms of post-transcriptional regulation by microRNAs: are the answers in sight? Nat Rev Genet 2008; 9: 102-14.
3. Orom UA, Nielsen FC, Lund AH. MicroRNA-10a binds the 5'UTR of ribosomal protein mRNAs and enhances their translation. Mol Cell 2008; 30: 460-71.
4. Friedman RC, Farh KK, Burge CB, Bartel DP. Most mammalian mRNAs are conserved targets of microRNAs. Genome Res 2009; 19: 92-105.
5. Lewis BP, Burge CB, Bartel DP. Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell 2005; 120: 15-20.
6. Lee RC, Feinbaum RL, Ambros V. The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell 1993; 75: 843-54.
7. Friedlander MR, Chen W, Adamidi C et al. Discovering microRNAs from deep sequencing data using miRDeep. Nat Biotechnol 2008; 26: 407-15.
8. Morin RD, O'Connor MD, Griffith M et al. Application of massively parallel sequencing to microRNA profiling and discovery in human embryonic stem cells. Genome Res 2008; 18: 610-21.
9. Griffiths-Jones S, Saini HK, van Dongen S, Enright AJ. miRBase: tools for microRNA genomics. Nucleic Acids Res 2008; 36: D154-8.
10. Calin GA, Croce CM. MicroRNA signatures in human cancers. Nat Rev Cancer 2006; 6: 857-66.
11. Melton C, Judson RL, Blelloch R. Opposing microRNA families regulate self-renewal in mouse embryonic stem cells. Nature 2010; 463: 621-6.
12. Valeri N, Gasparini P, Fabbri M et al. Modulation of mismatch repair and genomic stability by miR-155. Proc Natl Acad Sci USA 2010; 107: 6982-7.
13. O'Connell RM, Rao DS, Chaudhuri AA, Baltimore D. Physiological and pathological roles for microRNAs in the immune system. Nat Rev Immunol 2010; 10: 111-22.
14. Chen D, Farwell MA, Zhang B. MicroRNA as a new player in the cell cycle. J Cell Physiol 2010; 225: 296-301.
15. Najafi-Shoushtari SH, Kristo F, Li Y et al. MicroRNA-33 and the SREBP host genes cooperate to control cholesterol homeostasis. Science 2010; 328: 1566-9.
16. Calin GA, Dumitru CD, Shimizu M et al. Frequent deletions and down-regulation of micro-RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. Proc Natl Acad Sci USA 2002; 99: 15524-9.
17. Cimmino A, Calin GA, Fabbri M et al. miR-15 and miR-16 induce apoptosis by targeting BCL2. Proc Natl Acad Sci USA 2005; 102: 13944-9.
18. Lee YS, Dutta A. MicroRNAs in cancer. Annu Rev Pathol 2009; 4: 199-227.
19. Voorhoeve PM. MicroRNAs: oncogenes, tumor suppressors or master regulators of cancer heterogeneity? Biochim Biophys Acta 2010; 1805: 72-86.
20. He L, He X, Lowe SW, Hannon GJ. microRNAs join the p53 network - another piece in the tumour-suppression puzzle. Nat Rev Cancer 2007; 7: 819-22.
21. Tazawa H, Tsuchiya N, Izumiya M, Nakagama H. Tumor-suppressive miR-34a induces senescence-like growth arrest through modulation of the E2F pathway in human colon cancer cells. Proc Natl Acad Sci USA 2007; 104: 15472-7.
22. Tsuchiya N, Nakagama H. MicroRNA, SND1, and alterations in translational regulation in colon carcinogenesis. Mutat Res 2010; 693: 94-100.
23. Yamakuchi M, Ferlito M, Lowenstein CJ. miR-34a repression of SIRT1 regulates apoptosis. Proc Natl Acad Sci USA 2008; 105: 13421-6.
24. Lu J, Getz G, Miska EA et al. MicroRNA expression profiles classify human cancers. Nature 2005; 435: 834-8.
25. Kumar MS, Lu J, Mercer KL, Golub TR, Jacks T. Impaired microRNA processing enhances cellular transformation and tumorigenesis. Nat Genet 2007; 39: 673-7.
26. Karube Y, Tanaka H, Osada H et al. Reduced expression of Dicer associated with poor prognosis in lung cancer patients. Cancer Sci 2005; 96: 111-5.
27. Kozaki K, Imoto I, Mogi S, Omura K, Inazawa J. Exploration of tumor-suppressive microRNAs silenced by DNA hypermethylation in oral cancer. Cancer Res 2008; 68: 2094-105.
28. Osaki M, Takeshita F, Ochiya T. MicroRNAs as biomarkers and therapeutic drugs in human cancer. Biomarkers 2008; 13: 658-70.
29. Ahmed FE, Jeffries CD, Vos PW et al. Diagnostic microRNA markers for screening sporadic human colon cancer and active ulcerative colitis in stool and tissue. Cancer Genomics Proteomics 2009; 6: 281-95.
30. Kosaka N, Iguchi H, Ochiya T. Circulating microRNA in body fluid: a new potential biomarker for cancer diagnosis and prognosis. Cancer Sci 2010; 101: 2087-92.
31. Link A, Balaguer F, Shen Y et al. Fecal MicroRNAs as novel biomarkers for colon cancer screening. Cancer Epidemiol Biomarkers Prev 2010; 19: 1766-74.
32. Tsujiura M, Ichikawa D, Komatsu S et al. Circulating microRNAs in plasma of patients with gastric cancers. Br J Cancer 2010; 102: 1174-9.
33. Wang H, Ach RA, Curry B. Direct and sensitive miRNA profiling from low-input total RNA. RNA 2007; 13: 151-9.
34. Petersen M, Wengel J. LNA: a versatile tool for therapeutics and genomics. Trends Biotechnol 2003; 21: 74-81.
35. Baskerville S, Bartel DP. Microarray profiling of microRNAs reveals frequent coexpression with neighboring miRNAs and host genes. RNA 2005; 11: 241-7.
36. Izumiya M, Okamoto K, Tsuchiya N, Nakagama H. Functional screening using a microRNA virus library and microarrays: a new high-throughput assay to identify tumor-suppressive microRNAs. Carcinogenesis 2010; 31: 1354-9.
37. Nakano H, Miyazawa T, Kinoshita K, Yamada Y, Yoshida T. Functional screening identifies a microRNA, miR-491 that induces apoptosis by targeting Bcl-X(L) in colorectal cancer cells. Int J Cancer 2010; 127: 1072-80.
38. Voorhoeve PM, le Sage C, Schrier M et al. A genetic screen implicates miRNA-372 and miRNA-373 as oncogenes in testicular germ cell tumors. Cell 2006; 124: 1169-81.
39. Echeverri CJ, Perrimon N. High-throughput RNAi screening in cultured cells: a user's guide. Nat Rev Genet 2006; 7: 373-84.
40. Tsuchiya N, Izumiya M, Ogata-Kawata H et al. Tumor-suppressor miR-22 determines p53-dependent cellular fate through post-transcriptional regulation of p21. Cancer Res 2011; doi: 10.1158/0008-5472.CAN-10-2475 [Epub ahead of print].
41. Chivukula RR, Mendell JT. Circular reasoning: microRNAs and cell-cycle control. Trends Biochem Sci 2008; 33: 474-81.
42. Mendell JT. miRiad roles for the miR-17-92 cluster in development and disease. Cell 2008; 133: 217-22.
43. Mertens-Talcott SU, Chintharlapalli S, Li X, Safe S. The oncogenic microRNA-27a targets genes that regulate specificity protein transcription factors and the G2-M checkpoint in MDA-MB-231 breast cancer cells. Cancer Res 2007; 67: 11001-11.
44. Gramantieri L, Ferracin M, Fornari F et al. Cyclin G1 is a target of miR-122a, a microRNA frequently down-regulated in human hepatocellular carcinoma. Cancer Res 2007; 67: 6092-9.
45. Agirre X, Vilas-Zornoza A, Jimenez-Velasco A et al. Epigenetic silencing of the tumor suppressor microRNA Hsa-miR-124a regulates CDK6 expression and confers a poor prognosis in acute lymphoblastic leukemia. Cancer Res 2009; 69: 4443-53.
46. le Sage C, Nagel R, Egan DA et al. Regulation of the p27(Kip1) tumor suppressor by miR-221 and miR-222 promotes cancer cell proliferation. EMBO J 2007; 26: 3699-708.
47. Mott JL, Kobayashi S, Bronk SF, Gores GJ. mir-29 regulates Mcl-1 protein expression and apoptosis. Oncogene 2007; 26: 6133-40.
48. Ma L, Teruya-Feldstein J, Weinberg RA. Tumour invasion and metastasis initiated by microRNA-10b in breast cancer. Nature 2007; 449: 682-8.
49. Asangani IA, Rasheed SA, Nikolova DA et al. MicroRNA-21 (miR-21) post-transcriptionally downregulates tumor suppressor Pdcd4 and stimulates invasion, intravasation and metastasis in colorectal cancer. Oncogene 2008; 27: 2128-36.
50. Scott GK, Goga A, Bhaumik D, Berger CE, Sullivan CS, Benz CC. Coordinate suppression of ERBB2 and ERBB3 by enforced expression of micro-RNA miR-125a or miR-125b. J Biol Chem 2007; 282: 1479-86.
51. Wurdinger T, Tannous BA, Saydam O., et al. miR-296 regulates growth factor receptor overexpression in angiogenic endothelial cells. Cancer Cell. 2008; 14: 382-93.
52. Lee DY, Deng Z, Wang CH, Yang BB. MicroRNA-378 promotes cell survival, tumor growth, and angiogenesis by targeting SuFu and Fus-1 expression. Proc Natl Acad Sci USA 2007; 104: 20350-5.
53. Ohno M, Natsume A, Kondo Y et al. The modulation of microRNAs by type I IFN through the activation of signal transducers and activators of transcription 3 in human glioma. Mol Cancer Res 2009; 7: 2022-30.
54. Nakano H, Miyazawa T, Kinoshita K, Yamada Y, Yoshida T. Functional screening identifies a microRNA, miR-491 that induces apoptosis by targeting Bcl-X(L) in colorectal cancer cells. Int J Cancer 2010; 127: 1072-80.
55. Barbie DA, Tamayo P, Boehm JS et al. Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1. Nature 2009; 462: 108-12.
56. Schlabach MR, Luo J, Solimini NL et al. Cancer proliferation gene discovery through functional genomics. Science 2008; 319: 620-4.
57. Silva JM, Marran K, Parker JS et al. Profiling essential genes in human mammary cells by multiplex RNAi screening. Science 2008; 319: 617-20.
58. Ngo VN, Davis RE, Lamy L et al. A loss-of-function RNA interference screen for molecular targets in cancer. Nature 2006; 441: 106-10.
59. Brummelkamp TR, Fabius AW, Mullenders J et al. An shRNA barcode screen provides insight into cancer cell vulnerability to MDM2 inhibitors. Nat Chem Biol 2006; 2: 202-6.
60. Huang Q, Gumireddy K, Schrier M et al. The microRNAs miR-373 and miR-520c promote tumour invasion and metastasis. Nat Cell Biol 2008; 10: 202-10.
61. Berns K, Hijmans EM, Mullenders J et al. A large-scale RNAi screen in human cells identifies new components of the p53 pathway. Nature 2004; 428: 431-7.
62. Berns K, Horlings HM, Hennessy BT et al. A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer. Cancer Cell 2007; 12: 395-402.
63. Kolfschoten IG, van Leeuwen B, Berns K et al. A genetic screen identifies PITX1 as a suppressor of RAS activity and tumorigenicity. Cell 2005; 121: 849-58.
64. Westbrook TF, Martin ES, Schlabach MR et al. A genetic screen for candidate tumor suppressors identifies REST. Cell 2005; 121: 837-48.
65. Bric A, Miething C, Bialucha CU et al. Functional identification of tumor-suppressor genes through an in vivo RNA interference screen in a mouse lymphoma model. Cancer Cell 2009; 16: 324-35.